It was shown that the level of UCHL1 expression determined in tumor tissue by the immunohistochemical method was associated with an unfavorable outcome in patients with LC and breast cancer, and that this protein could serve as a target for targeted therapy [33]. This evidence concerns the gene UCHL1 and laryngotracheoesophageal cleft.